All In Biotech

Drug Trial Radar · NCT01039948

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

A Phase 1b/2 Study of AV-299 (Formerly SCH 900105) in Combination With Gefitinib in Asian Subjects With Non-Small Cell Lung Cancer (P06162)

Last checked: Nov 20, 2026Latest source record: Apr 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 203 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

203

Actual

Start

Dec 2009

Primary completion

Aug 2013

Study completion Aug 2013

Sponsor

Lead sponsor
AVEO Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 25, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

During Phase 1b portion, there will be a dose-escalation of AV-299 (formerly SCH 900105) in combination with the recommended dose of gefitinib in subjects with NSCLC or advanced solid tumor. The objective is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended Phase 2 dose (RP2D) in combination with gefitinib for the Phase 2 portion. The Phase 2 is an open-label, 2-arm, randomized study designed to compare the combination of AV-299 (formerly SCH900105) and gefitinib versus gefitinib alone in clinically selected Asian subjects with previously untreated lung adenocarcinoma who have a high likelihood of harboring activating EGFR mutations. Subjects who progress after initial disease control in the gefitinib alone arm may crossover to the combination arm.

Conditions

  • Carcinoma, Non-Small Cell-Lung
  • Lung Neoplasms
  • Lung Cancer
  • Respiratory Tract Neoplasms

Interventions

  • AV-299 + gefitinibBiological

    AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.

  • GefitinibDrug

    Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Dose Limiting Toxicity and Recommended Phase II DoseTime frame: Every 4 weeks for the first 4 months of treatment period, every 8 weeks thereaftert
  2. Phase 2: Objective Response RateTime frame: Every 4 weeks for the first 4 months of treatment period, every 8 weeks thereafter

Locations

26 sites in 7 countries. Site status is shown where the registry gives one.

  • Investigational Site 1

    Shatin N.T., Hong Kong

  • Investigational Site 10

    Kuala Lumpur, Malaysia

  • Investigational Site 9

    Kuala Lumpur, Malaysia

  • Investigational Site 11

    Kuala Pahang, Malaysia

  • Investigational Site 12

    Manila, Philippines

  • Investigational Site 13

    Pasig, Philippines

  • Investigational Site 14

    Quezon City, Philippines

  • Investigational Site 15

    Singapore, Singapore

  • Investigational Site 2

    Chungcheongbuk-do, South Korea

  • Investigational Site 3

    Gyeonggi-do, South Korea

  • Investigational Site 4

    Jeollanam-do, South Korea

  • Investigational Site 5

    Seoul, South Korea

  • Investigational Site 6

    Seoul, South Korea

  • Investigational Site 7

    Seoul, South Korea

  • Investigational Site 8

    Seoul, South Korea

  • Investigational Site 16

    Changhua, Taiwan

  • Investigational Site 17

    Chiayi City, Taiwan

  • Investigational Site 18

    Taichung, Taiwan

  • Investigational Site 19

    Tainan, Taiwan

  • Investigational Site 20

    Taipei, Taiwan

  • Investigational Site 21

    Taipei, Taiwan

  • Investigational Site 22

    Taoyuan, Taiwan

  • Investigational Site 23

    Bangkok, Thailand

  • Investigational Site 24

    Chiang Mai, Thailand

  • Investigational Site 25

    KhonKaen, Thailand

  • Investigational Site 26

    Songkhla, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.